TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38025806

Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy for stage IIIA (30.2%) and stage IIIB (37.0%) patients
Number of subjects: 1838

Group type: EXPERIMENTAL
Intervention: Surgical resection (26.3% overall; 37.0% for stage IIIA and 11.1% for stage IIIB)
Number of subjects: 1838
Study: 38025971

Group type: EXPERIMENTAL
Intervention: Fecal lactoferrin trajectory (high/moderate-rapid decrease)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fecal lactoferrin trajectory (moderate-slow decrease, high-slow decrease, high-stable)
Number of subjects: 0
Study: 38026297

Group type: EXPERIMENTAL
Intervention: Peer-led BASICS intervention
Number of subjects: 308
Study: 38026295

Group type: EXPERIMENTAL
Intervention: Salt reduction program
Number of subjects: 311

Group type: COMPARATOR
Intervention: Healthy lifestyle general program
Number of subjects: 311
Study: 38026375

Group type: EXPERIMENTAL
Intervention: Aggressive warming
Number of subjects: 309

Group type: COMPARATOR
Intervention: Routine warming
Number of subjects: 309
Study: 38026401

Group type: EXPERIMENTAL
Intervention: Guaranteed income ($500/month) during the first 12-months of follow-up (Phase I)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Waitlist arm participants (Control)
Number of subjects: 300
Study: 38026477

Group type: EXPERIMENTAL
Intervention: Diaphragmatic relaxing incision added to crural repair
Number of subjects: 0

Group type: COMPARATOR
Intervention: Crural repair alone (Control)
Number of subjects: 0
Study: 38026571

Group type: EXPERIMENTAL
Intervention: Openfit (automated identification)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Openfit (semiautomated identification)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Openfit (automated energy estimates)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Openfit (semiautomated energy estimates)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: User Satisfaction Survey (USS)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Computer Systems Usability Questionnaire (CSUQ)
Number of subjects: 24
Study: 38026755

Group type: EXPERIMENTAL
Intervention: 3-point Severity Scale of ARIA-E (SSAE-3)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 5-point Severity Scale of ARIA-E (SSAE-5)
Number of subjects: 75
Study: 38026913

Group type: EXPERIMENTAL
Intervention: Single drain
Number of subjects: 196
Study: 38027064

Group type: EXPERIMENTAL
Intervention: tremtelectogene empogeditemcel (trem-cel)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: trem-cel
Number of subjects: 0
Study: 38027106

Group type: EXPERIMENTAL
Intervention: Exenatide 2 mg weekly injections
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 38027217

Group type: EXPERIMENTAL
Intervention: Chronic hypoparathyroidism patients
Number of subjects: 161
Study: 38027419

Group type: EXPERIMENTAL
Intervention: 0.2-μg/day fluocinolone acetonide implant (FAi)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Sham injection
Number of subjects: 153
Study: 38027469

Group type: EXPERIMENTAL
Intervention: Oral Ambroxol (ABX) 1.2 g/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 38028143

Group type: EXPERIMENTAL
Intervention: CF33-hNIS-anti-PD-L1 oncolytic virus followed by trastuzumab-deruxtecan (T-DXd)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Trastuzumab-deruxtecan (T-DXd)
Number of subjects: 0
Study: 38028146

Group type: EXPERIMENTAL
Intervention: Chemotherapy alone (40.4%)
Number of subjects: 421

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus surgery (33.8%)
Number of subjects: 421

Group type: EXPERIMENTAL
Intervention: Sequential chemoradiotherapy (CRT) (17.6%)
Number of subjects: 421

Group type: EXPERIMENTAL
Intervention: Concurrent CRT (9.3%)
Number of subjects: 421

Group type: EXPERIMENTAL
Intervention: Definite radiotherapy (5.0%)
Number of subjects: 421

Group type: EXPERIMENTAL
Intervention: Surgery alone (20.6%)
Number of subjects: 421

Group type: EXPERIMENTAL
Intervention: Other surgery (20.6%)
Number of subjects: 421
Study: 38028163

Group type: EXPERIMENTAL
Intervention: Dietician-led dietary intervention
Number of subjects: 156

Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 156
Study: 38028272

Group type: EXPERIMENTAL
Intervention: therapeutic acute intermittent hypoxia (tAIH)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: transcutaneous spinal stimulation-enhanced walking therapy (WALK)
Number of subjects: 0
Study: 38028429

Group type: EXPERIMENTAL
Intervention: Remote electrical neuromodulation (REN) device used for acute treatment of migraine, applied for 45 minutes, used on at least 10 days every 28-day month
Number of subjects: 83
Study: 38028436

Group type: EXPERIMENTAL
Intervention: Skin cancer prevention information
Number of subjects: 578
Study: 38028977

Group type: EXPERIMENTAL
Intervention: Internet-based cognitive-behavioral therapy (9 sessions)
Number of subjects: 65
Study: 38028985

Group type: EXPERIMENTAL
Intervention: EBV-positive diffuse large B-cell lymphoma treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EBV-positive classic Hodgkin lymphoma treatment
Number of subjects: 0
Study: 38029215

Group type: EXPERIMENTAL
Intervention: Pugongying granules
Number of subjects: 37

Group type: COMPARATOR
Intervention: Cefdinir
Number of subjects: 37
Study: 38029356

Group type: EXPERIMENTAL
Intervention: Recombinant erythropoietin (rEPO) - Epoetin alpha 40,000 international units per week administered subcutaneously until hemoglobin (Hb) >11 g/dL and then tapered off.
Number of subjects: 47

Group type: COMPARATOR
Intervention: AIHA population not treated with rEPO (control group).
Number of subjects: 47
Study: 38029357

Group type: EXPERIMENTAL
Intervention: Fol-CHOP (pralatrexate 30 mg/m2 combined with CHOP)
Number of subjects: 33
Study: 38029386

Group type: EXPERIMENTAL
Intervention: Quality improvement intervention (online educational module, intraoperative checklist, harmonized surgical techniques)
Number of subjects: 3268

Group type: EXPERIMENTAL
Intervention: High engagement centres (at least 80% of surgeons completed educational modules)
Number of subjects: 3268

Group type: EXPERIMENTAL
Intervention: Low engagement hospitals (less than 50% of surgeons completed educational modules)
Number of subjects: 3268
Study: 38029625

Group type: EXPERIMENTAL
Intervention: EHS/attributers
Number of subjects: 2040

Group type: COMPARATOR
Intervention: Non-EHS
Number of subjects: 2040

Group type: EXPERIMENTAL
Intervention: T-allele of variant rs2302729 of CACNA1C
Number of subjects: 2040
Study: 38029689

Group type: EXPERIMENTAL
Intervention: Bee Buzzy
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Bee Buzzy and puppet
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control
Number of subjects: 105
Study: 38029807

Group type: EXPERIMENTAL
Intervention: Neuron-specific knockdown of p75NTR
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: p75NTR inhibitor LM11A-31
Number of subjects: 0
Study: 38029831

Group type: EXPERIMENTAL
Intervention: Previous immune checkpoint inhibitor therapy (ICI)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Non-ICI
Number of subjects: 120
Study: 38030064

Group type: EXPERIMENTAL
Intervention: Nintedanib
Number of subjects: 407

Group type: COMPARATOR
Intervention: Pirfenidone
Number of subjects: 407
Study: 38030258

Group type: EXPERIMENTAL
Intervention: 4 g EPA ethyl ester (icosapent ethyl (IPE; Vascepa)) daily
Number of subjects: 388

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 388
Study: 38030303

Group type: EXPERIMENTAL
Intervention: NIS793 plus spartalizumab (NIS793 0.3-30 mg/kg Q3W and spartalizumab 300 mg Q3W or NIS793 20-30 mg/kg Q2W and spartalizumab 400 mg Q4W)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: NIS793 monotherapy (0.3-1 mg/kg every 3 weeks)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: NIS793 plus spartalizumab (at recommended dose for expansion)
Number of subjects: 120
Study: 38030319

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa (10 μg/kg subcutaneously once a week for 8 weeks)
Number of subjects: 76
Study: 38030318

Group type: EXPERIMENTAL
Intervention: Danicopan plus ravulizumab or eculizumab
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo plus ravulizumab or eculizumab
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Danicopan
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study: 38030558

Group type: EXPERIMENTAL
Intervention: Bone mineral density (BMD) gain
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Bone mineral density (BMD) loss
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Bone loss occurrence
Number of subjects: 209
Study: 38030962

Group type: EXPERIMENTAL
Intervention: Prophylactic treatment (76.2% of participants)
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Body weight >30 kg/m
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Poorer joint health
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: BMI >30
Number of subjects: 269
Study: 38030971

Group type: EXPERIMENTAL
Intervention: Phosphocreatine (PCr)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (normosaline)
Number of subjects: 120
Study: 38030975

Group type: EXPERIMENTAL
Intervention: Modified diagnostic strategy combining the YEARS rule and age-adjusted D-dimer threshold
Number of subjects: 1414

Group type: COMPARATOR
Intervention: Control group using age-adjusted D-dimer threshold only
Number of subjects: 1414
Study: 38030988

Group type: EXPERIMENTAL
Intervention: REFRAME intervention (behavioral activation component)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Active control intervention (psycho-education and mindful monitoring)
Number of subjects: 81
Study: 38030991

Group type: EXPERIMENTAL
Intervention: e-visit intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 0
Study: 38031004

Group type: EXPERIMENTAL
Intervention: Communication practices during patient-nurse consultations
Number of subjects: 150
Study: 38031020

Group type: COMPARATOR
Intervention: Vaginal CO (VagLaser)
Number of subjects: 0
Study: 38031088

Group type: EXPERIMENTAL
Intervention: Schedule-I group (3 DC injections with 28-day interval)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Schedule-II group (3 DC injections with 7-day interval for first course, then 28-day interval)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Soft-tissue sarcomas (n=13)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Osteosarcomas (n=6)
Number of subjects: 19
Study: 38031116

Group type: EXPERIMENTAL
Intervention: Airway occlusion maneuvers (Pocc, P0.1, PMI)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Airway occlusion maneuvers (PMI)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Airway occlusion maneuvers (P0.1)
Number of subjects: 97
Study: 38031156

Group type: EXPERIMENTAL
Intervention: Cadence thresholds of ≥ 105 steps/min for moderate intensity
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Cadence thresholds of ≥ 115 steps/min or ≥ 120 steps/min for vigorous intensity
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Cadence thresholds ranging from 105.9 to 112.8 steps/min for relatively-defined moderate intensity
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Cadence thresholds ranging from 126.1-132.1 steps/min for vigorous intensity
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Cadence thresholds ranging from 102.0-104.3 steps/min for relatively-defined moderate intensity
Number of subjects: 97
Study: 38031180

Group type: EXPERIMENTAL
Intervention: HCS-KY OEND program (naloxone distribution)
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Naloxone distribution by partner organizations
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: County-level naloxone distribution
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Sustainability meeting attendance
Number of subjects: 209
Study: 38031584

Group type: COMPARATOR
Intervention: 12 weeks of cognitive-behavioral therapy (CBT)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 24 weeks of cognitive-behavioral therapy (CBT)
Number of subjects: 45
Study: 38031761

Group type: EXPERIMENTAL
Intervention: Recovery from uninvolved heavy/light chain pair immunoparesis (uHLC IP) after the first year of maintenance
Number of subjects: 0

Group type: COMPARATOR
Intervention: Classic immunoparesis (IP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recovery from uHLC IP after the first year of maintenance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MRD status and uHLC IP recovery
Number of subjects: 0
Study: 38031911

Group type: COMPARATOR
Intervention: Online intervention to address mental health
Number of subjects: 0
Study: 38031973

Group type: EXPERIMENTAL
Intervention: INCRAFT System
Number of subjects: 150
Study: 38032115

Group type: EXPERIMENTAL
Intervention: SleepWell24 smartphone application
Number of subjects: 87

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 87
Study: 38032247

Group type: EXPERIMENTAL
Intervention: Arm crank exercise training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 38032260

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 38032261

Group type: EXPERIMENTAL
Intervention: Wearable cardioverter-defibrillator (WCD) during cardiac rehabilitation (CR)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation (CR)
Number of subjects: 55
Study: 38032277

Group type: EXPERIMENTAL
Intervention: Plant Fiber Extract (PFE)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chocolate containing PFE
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 38032448

Group type: EXPERIMENTAL
Intervention: Patients with postreperfusion syndrome (PRS)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Patients without postreperfusion syndrome (non-PRS)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Patients with PRS
Number of subjects: 34
Study: 38032504

Group type: EXPERIMENTAL
Intervention: Age-T index (≥4.9)
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Age-T index (cut-off ≥4.9)
Number of subjects: 450
Study: 38032573

Group type: EXPERIMENTAL
Intervention: Aficamten in addition to standard-of-care medications
Number of subjects: 282

Group type: COMPARATOR
Intervention: Placebo in addition to standard-of-care medications
Number of subjects: 282
Study: 38032582

Group type: EXPERIMENTAL
Intervention: Women with prior VT/VF
Number of subjects: 714

Group type: EXPERIMENTAL
Intervention: White women with prior VT/VF
Number of subjects: 714

Group type: EXPERIMENTAL
Intervention: Black women with prior VT/VF
Number of subjects: 714
Study: 38032621

Group type: EXPERIMENTAL
Intervention: Guided i-CBT
Number of subjects: 1319

Group type: EXPERIMENTAL
Intervention: Self-guided i-CBT
Number of subjects: 1319

Group type: COMPARATOR
Intervention: TAU
Number of subjects: 1319
Study: 38032624

Group type: EXPERIMENTAL
Intervention: Active hypoglossal nerve stimulation (HGNS) therapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham hypoglossal nerve stimulation (HGNS) therapy
Number of subjects: 60
Study: 38032640

Group type: EXPERIMENTAL
Intervention: Specific Auricular Acupuncture (SA)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Nonspecific Auricular Acupuncture (NSA)
Number of subjects: 74
Study: 38032643

Group type: EXPERIMENTAL
Intervention: Skin-to-skin contact (SSC) with either parent initiated at birth and continued for the first 6 hours after birth.
Number of subjects: 71

Group type: COMPARATOR
Intervention: Standard incubator care.
Number of subjects: 71
Study: 38032644

Group type: EXPERIMENTAL
Intervention: Vegan diet
Number of subjects: 44

Group type: COMPARATOR
Intervention: Omnivorous diet
Number of subjects: 44
Study: 38032645

Group type: EXPERIMENTAL
Intervention: 900 mg high-protease pancreatic replacement therapy
Number of subjects: 190

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 190
Study: 38032712

Group type: EXPERIMENTAL
Intervention: CEASE intervention for smoking cessation
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 100
Study: 38032857

Group type: EXPERIMENTAL
Intervention: wMel-infected Aedes aegypti mosquito releases
Number of subjects: 3300000

Group type: EXPERIMENTAL
Intervention: wMel-treated neighbourhoods
Number of subjects: 3300000
Study: 38033143

Group type: EXPERIMENTAL
Intervention: Treatment goals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Life goals
Number of subjects: 0
Study: 38033276

Group type: EXPERIMENTAL
Intervention: Gross Motor Ability Estimator-2 (GMAE-2)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Gross Motor Ability Estimator-3 (GMAE-3)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Gross Motor Ability Estimator-2 (GMAE-2) and Gross Motor Ability Estimator-3 (GMAE-3)
Number of subjects: 53
Study: 38033284

Group type: EXPERIMENTAL
Intervention: Bosutinib 400 mg/m
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Bosutinib 300 mg/m
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Bosutinib 350 mg/m
Number of subjects: 30
Study: 38033321

Group type: EXPERIMENTAL
Intervention: Metabolomic profiling (GC-MS, CE-MS, and LC-MS)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control group of 68 non-cancer individuals
Number of subjects: 77
Study: 38033375

Group type: EXPERIMENTAL
Intervention: tablet-based serious game therapy (SGT), 4 months, four 20-min sessions/week
Number of subjects: 150

Group type: COMPARATOR
Intervention: conventional cognitive exercises, 4 months, four 20-min sessions/week
Number of subjects: 150
Study: 38033459

Group type: EXPERIMENTAL
Intervention: Oral cannabidiol 600 mg/d
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 38033548

Group type: EXPERIMENTAL
Intervention: Tasimelteon
Number of subjects: 1
Study: 38033615

Group type: EXPERIMENTAL
Intervention: Seropositive for NMDAR1-abs (IgM/IgA/IgG)
Number of subjects: 583

Group type: EXPERIMENTAL
Intervention: Seropositive with low titers (≤1:100)
Number of subjects: 583

Group type: EXPERIMENTAL
Intervention: Seropositive with high titers (>1:100)
Number of subjects: 583

Group type: COMPARATOR
Intervention: Seronegative for NMDAR1-abs
Number of subjects: 583
Study: 38033649

Group type: EXPERIMENTAL
Intervention: EKS
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: SSE
Number of subjects: 128

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study: 38034010

Group type: EXPERIMENTAL
Intervention: Green-MED diet (high polyphenols, low carbohydrates, includes green tea 3-4 cups/day and Wolffia-globosa Mankai plant shake)
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Mediterranean (MED) diet (hypocaloric, lower in carbohydrates, includes walnuts 28 g/day)
Number of subjects: 294

Group type: COMPARATOR
Intervention: Healthy dietary guidelines (HDG)
Number of subjects: 294
Study: 38034378

Group type: EXPERIMENTAL
Intervention: High blood pressure variability (BPV)
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: High nocturnal heart rate variability (HRV)
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: Endothelial function
Number of subjects: 359
Study: 38034452

Group type: EXPERIMENTAL
Intervention: Ondansetron
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no Ondansetron)
Number of subjects: 0
Study: 38034535

Group type: EXPERIMENTAL
Intervention: 1064-nm Nd:YAG picosecond laser using fractional micro-lens array (P-MLA)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Ablative fractional 2940-nm Er:YAG laser (AF-Er)
Number of subjects: 31
Study: 38034693

Group type: EXPERIMENTAL
Intervention: Supervised out-of-bed mobilisation and physical activity training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Wearable activity tracker
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Linear and logistic regression models
Number of subjects: 0
Study: 38034882

Group type: EXPERIMENTAL
Intervention: Mirikizumab 300 mg intravenous every 4 weeks for 12 weeks
Number of subjects: 1162

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1162
Study: 38035037

Group type: EXPERIMENTAL
Intervention: Icosapent ethyl (IPE) 4 g/day
Number of subjects: 8179

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8179
Study: 38035038

Group type: EXPERIMENTAL
Intervention: Posterior pericardiotomy
Number of subjects: 420

Group type: COMPARATOR
Intervention: Control group (no posterior pericardiotomy)
Number of subjects: 420
Study: 38035176

Group type: EXPERIMENTAL
Intervention: Enroll-HD observational study
Number of subjects: 15982

Group type: EXPERIMENTAL
Intervention: Core assessments at annual visits
Number of subjects: 15982

Group type: EXPERIMENTAL
Intervention: EHDPA (Enroll-HD Phenotype Atlas)
Number of subjects: 15982
Study: 38035207

Group type: EXPERIMENTAL
Intervention: Half Fourier Single-Shot Turbo Spin-Echo (HASTE) sequence
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 3D Balanced Steady-State Free Precession (bSSFP) sequence
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: HASTE sequence in key cardiac planes
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Cardiac conduction system contours
Number of subjects: 5
Study: 38035216

Group type: EXPERIMENTAL
Intervention: BFR group (pneumatic cuff at 80% limb occlusion pressure)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: BFR group
Number of subjects: 46
Study: 38035291

Group type: EXPERIMENTAL
Intervention: Italian version of the Elderly Mobility Scale (I-EMS)
Number of subjects: 10
Study: 38035363

Group type: EXPERIMENTAL
Intervention: 15 g specific collagen peptides (SCP)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 55
Study: 38035641

Group type: EXPERIMENTAL
Intervention: Fasting plasma glucose (FPG) reduction
Number of subjects: 1895

Group type: EXPERIMENTAL
Intervention: Postprandial glucose (PPG) reduction
Number of subjects: 1895

Group type: EXPERIMENTAL
Intervention: FPG and PPG reductions
Number of subjects: 1895
Study: 38035655

Group type: EXPERIMENTAL
Intervention: PVC group
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study: 38035725

Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab
Number of subjects: 1954

Group type: COMPARATOR
Intervention: Nivolumab monotherapy
Number of subjects: 1954
Study: 38035737

Group type: EXPERIMENTAL
Intervention: Add-on pramipexole for 9 weeks
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Open-label treatment after RCT phase
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo for 9 weeks
Number of subjects: 80
Study: 38035747

Group type: EXPERIMENTAL
Intervention: Icatibant (bradykinin inhibitor)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0